Company / Accounts Receivable
NEKTAR THERAPEUTICS Accounts Receivable History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.2M
FY2023
5-year range
$1.2M / $22.5M
FY2019-FY2023
Trend
-79.9%
vs FY2022
Sector context
#105 of 115
Health Care
What the data says
Among 115 Health Care companies, NEKTAR THERAPEUTICS is in the bottom 9% for accounts receivable. Accounts Receivable has declined for 3 consecutive years, from $39M in FY2020 to $1M in FY2023.
Based on SEC 10-K filings.
$1M in FY2023 with a 5-year CAGR of -51.1%.
Declined from $22M to $1M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -68.6%
- 5-Year CAGR
- -51.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 115This company $1.2M Sector average $1.1B
▼
-99.9% below sector average
Key checks
Key Insights
- NEKTAR THERAPEUTICS's accounts receivable has declined for 3 consecutive years.
- 5-year CAGR of -51.1%, indicating a declining trend.
- In FY2023, accounts receivable decreased 79.9% year-over-year.
- Ranks #105 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $1.2M | -79.9% |
| FY2022 | $6.0M | -73.4% |
| FY2021 | $22.5M | -42.2% |
| FY2020 | $38.9M | +5.7% |
| FY2019 | $36.8M | -14.8% |
| FY2018 | $43.2M | +761.8% |
| FY2017 | $5.0M | -68.0% |
| FY2016 | $15.7M | -21.4% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026